Board of Directors
Lee Golden, M.D., Chairman of the Board of Directors
Dr. Golden is currently Chief Medical Officer at Gemphire (NASDAQ:GEMP), a clinical-stage biopharmaceutical company that is developing and commercializing therapies to help patients with cardiometabolic disorders, including dyslipidemia and NASH. Prior to that, he served as Senior VP, Therapeutic Business Unit Head for Cardiovascular, Pulmonary and Central Nervous System at Mesoblast (NASDAQ:MESO). Dr. Golden is an expert in the oversight of large cardiovascular trials and development of new cardiovascular/blood therapeutics. He has served as Executive Director of Neuroscience and Ophthalmology at Novartis Pharmaceuticals, Cardiovascular Executive Director at Eisai Medical Research, and Cardiovascular Team Leader/Medical Director at Pfizer Pharmaceuticals. Dr. Golden has managed global cross-functional teams responsible for creating and implementing strategic development and commercial plans. Dr. Golden is a graduate of New York University School of Medicine and is formally trained as an Interventional Cardiologist.
Sheldon Goldstein, M.D.
Dr. Goldstein is the inventor of the MCTS device and the visionary behind the Company’s blood transfusion related Intellectual Property. Dr. Goldstein is an Internist & Cardiac Anesthesiologist practicing at Montefiore Medical Center, having received his medical degree at Hahnemann Medical College in Philadelphia (renamed Drexel/Hahnemann). Dr. Goldstein is an expert in the management of bleeding patients, and has been invited to speak on coagulation and transfusion topics on multiple occasions.